Study: NCT00669617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI